Squawk Pod Regeneron CEO on 23andMe & $275m in Margaritaville 6/11/25
Jun 11, 2025
Len Schleifer, Founder and CEO of Regeneron, discusses the potential acquisition of 23andMe, emphasizing the value of genetic data in drug development. He highlights how DNA insights can shape future therapies. Meanwhile, Robert Frank dives into the legal complexities surrounding Jimmy Buffett's $275 million estate amid fierce disputes between trustees. The episode tackles the intersection of healthcare innovation and personal legacies, revealing both the promise and challenges of navigating genetic information and wealth distribution.
AI Snips
Chapters
Transcript
Episode notes
Regeneron Denies China Ties
- Regeneron CEO Len Schleifer denies close ties to the Chinese Communist Party despite congressional concerns.
- He explains Regeneron's business is primarily through non-Chinese companies selling their drugs in China, not direct engagement.
Genetics Drives Drug Discovery
- Genetic data, when analyzed in a de-identified way, helps identify how genes determine health and discover drug therapies.
- Regeneron has used genetics to predict drug indications, such as for allergic diseases with their drug Dupixent.
Value of Large Genetic Databases
- Acquiring a large de-identified genetic database is valuable for accelerating drug discovery.
- Integrating genetic data with health information enables targeted identification of drug candidates.